How Far Can the GLP-1 Wave Go?

Surging GLP-1 demand accelerates moves toward easier delivery, expanded capacity and faster innovation

13 Nov 2025

A surge in demand for GLP-1 receptor agonist therapies is reshaping the U.S. metabolic-care market, accelerating efforts by drugmakers to streamline treatment and expand manufacturing capacity. Once a narrow field, these medications have become central to weight-management and diabetes care, with 2024 adoption estimates indicating that hundreds of thousands of Americans have recently begun using them for weight control.

The rapid growth has reordered development priorities. Companies are advancing candidates designed to reduce treatment complexity, though many remain under review. According to company statements, Novo Nordisk is pursuing oral GLP-1 options intended to reduce barriers to use, while Eli Lilly is developing long-acting formulations that aim to provide steadier therapeutic effects and require fewer injections. These efforts signal a broad push toward convenience, even as widespread availability may be several cycles away.

Industrial infrastructure is expanding alongside product pipelines. In July 2024, CordenPharma announced an estimated €900 million expansion of its peptide platform across the United States and Europe to support rising GLP-1 volumes. Executives characterized the investment as a necessary step for a market that has shifted from specialized to strategically central, reflecting how manufacturing networks are being redesigned to meet growing demand.

Analysts say the shift underscores a wider recalibration within the pharmaceutical industry. Patients increasingly seek therapies that fit easily into daily routines, while insurers are examining long-term value, adherence patterns and overall outcomes. As competition intensifies, companies are focusing on formulations that preserve clinical benefit without adding cost or complexity. These dynamics could influence pricing strategies and market access decisions as the category matures.

Still, expectations for continued growth remain strong. The momentum behind GLP-1 treatments is drawing new partnerships, speeding research timelines and encouraging broader models of care. Market observers note that the coming year may bring notable progress as manufacturers attempt to define the next phase of metabolic therapy.

If current trends hold, GLP-1 therapies may become among the most influential forces in U.S. health-care innovation, attracting sustained attention from clinicians, investors and industry leaders as the field continues to evolve.